ID   MCF-7/CG-5/Dx
AC   CVCL_4D05
SY   CG5/Dx
DR   cancercelllines; CVCL_4D05
DR   Wikidata; Q54811574
RX   PubMed=8712686;
CC   Population: Caucasian.
CC   Doubling time: 47 hours (PubMed=8712686).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4D04 ! MCF-7/CG-5
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 05-10-23; Version: 15
//
RX   PubMed=8712686;
RA   Gibelli N., Zibera C., Asti A., Maestri L., Bacchella L.,
RA   Pedrazzoli P., Calligaro A., Robustelli della Cuna G.;
RT   "CG5/Dx human breast cancer cell line: characterization of a new
RT   doxorubicin-resistant variant.";
RL   Anticancer Res. 16:1675-1681(1996).
//